ClinicalTrialsFinder
RecruitingNCT07652736

A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)

A Real-World Evaluation of Tislelizumab Treatment Patterns and Effectiveness in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Sponsor

BeOne Medicines

Enrollment

440 participants

Start Date

Jun 5, 2026

Study Type

OBSERVATIONAL

Conditions

Extensive-stage Small-cell Lung CancerAdvanced Non-Small Cell Lung Cancer

Summary

The purpose of this study is to collect real-world data on treatment patterns and clinical outcomes in European patients receiving tislelizumab in routine clinical practice

Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • Participants are eligible to be included in the study only if they meet all the following criteria:
  • Participants or their legal representative must sign written inform consent form (ICF)
  • Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described.
  • Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study.

Exclusion Criteria4

  • Participants are excluded from the study if they meet any of the following criteria:
  • Participants who are unable to understand all implications of study participation.
  • Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab.
  • Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTislelizumab

Administered as part of routine clinical practice as determined by the treating physician in accordance with the summary of product characteristics (SmPC) and local standard of care

Locations(1)

Hospital General de Segovia

Segovia, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07652736

Related Trials

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

NCT06646276183 locations

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128158 locations

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT0509917294 locations

A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer

NCT068076327 locations

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

NCT046998385 locations